Agenus Inc (AGEN)

$7.50 -0.41 (-5.18%)
Market Cap 353.99M
Revenue (ttm) 114.20M
Net Income (ttm) 120,000.00
EPS (ttm) N/A
PE Ratio 2.63
Forward PE N/A
Profit Margin 0.11%
Debt to Equity Ratio -0.13
Volume 1,573,500
Avg Vol 4,837,950
Day's Range N/A - N/A
Shares Out 44.75M
Stochastic %K 84%
Beta 1.55
Analysts Strong Sell
Price Target $18.00

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGE...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
BlackW1d0w
BlackW1d0w Jul. 31 at 9:33 PM
$AGEN The key event will be the initial efficacy data. If those results are far better than current standards of care, the probability of an Accelerated Approval pathway increases meaningfully
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Jul. 31 at 5:13 PM
$AGEN why are we down, that greedy mf using ATM? C’mon commodore tell us the board members!! Wonder how many phone calls commodore has had to make to Agenus since the deal was announced to ask garo “what the fuck are you doing”
2 · Reply
pedmac2000
pedmac2000 Jul. 31 at 4:20 PM
$AGEN profit taking today ?
3 · Reply
Biotechguy21
Biotechguy21 Jul. 31 at 3:49 PM
$AGEN is it classic atm Friday in the ceo/cfo’s world?
0 · Reply
Biotechguy21
Biotechguy21 Jul. 31 at 1:57 PM
$AGEN don’t forget this ceo is responsible for these other pos stocks $INKT $PTIX epic legacy 🤡🤡😂😂💩💩💰💰
0 · Reply
BakerBrother
BakerBrother Jul. 31 at 1:23 PM
$AGEN funding secured and now the sky is the limit
2 · Reply
BakerBrother
BakerBrother Jul. 31 at 1:22 PM
$AGEN Ha ha ha ha ha idiot https://www.cnbc.com/amp/2026/07/30/leopold-aschenbrenners-hedge-fund-is-facing-steep-ai-losses.html
1 · Reply
Stefman9
Stefman9 Jul. 31 at 9:42 AM
$AGEN
1 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 3:16 AM
$AGEN First off my tip to you is NEVER buy biotech shares early. And if you find out that you did buy too early average down, average down, average down. I bought low 2s and even more when under 2. My first purchase was near 5 on the way down. If the science is good and the TAM is respectable stay with it. See TRIB below. .34 to 13.55 figure it out. Garo made me a boat load of cash in the early 2000s with ELAN.
5 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Jul. 31 at 2:51 AM
$AGEN Robbie, why are you such a garo fan boy? After all the reverse splits it would take share price of 100 to break even on original investment, would take share price of 300 dollars to get back to where we’d be if we had only invested in S&P and never stumbled across antigenics until now
0 · Reply
Latest News on AGEN
Agenus Slides: Corporate presentation

Jul 30, 2026, 9:00 AM EDT - 1 day ago

Agenus Slides: Corporate presentation

Agenus price target raised to $14 from $8 at B. Riley

2026-07-30T12:37:16.000Z - 1 day ago

Agenus price target raised to $14 from $8 at B. Riley

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Jul 28, 2026, 4:30 PM EDT - 3 days ago

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Agenus Registration statement: Registration filing

Jul 20, 2026, 8:00 AM EDT - 11 days ago

Agenus Registration statement: Registration filing

Agenus files to sell 2.13M shares of common stock for holders

2026-07-20T10:10:56.000Z - 11 days ago

Agenus files to sell 2.13M shares of common stock for holders

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Jul 17, 2026, 10:28 AM EDT - 14 days ago

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Why Is Agenus (AGEN) Stock Up Today?

2026-07-13T16:51:30.000Z - 18 days ago

Why Is Agenus (AGEN) Stock Up Today?

Agenus price target raised to $30 from $23 at H.C. Wainwright

2026-07-13T16:20:13.000Z - 18 days ago

Agenus price target raised to $30 from $23 at H.C. Wainwright

Agenus announces strategic prioritization of neoadjuvant BOT+BAL

2026-07-13T16:20:08.000Z - 18 days ago

Agenus announces strategic prioritization of neoadjuvant BOT+BAL

Agenus Transcript: Investor update

Jul 13, 2026, 8:30 AM EDT - 18 days ago

Agenus Transcript: Investor update

Agenus Press release: Investor update

Jul 13, 2026, 8:30 AM EDT - 18 days ago

Agenus Press release: Investor update

Agenus Slides: Investor update

Jul 13, 2026, 8:30 AM EDT - 18 days ago

Agenus Slides: Investor update

Agenus announces $340M private placement

2026-07-13T10:05:12.000Z - 18 days ago

Agenus announces $340M private placement

LGND

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Jul 13, 2026, 6:00 AM EDT - 18 days ago

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Agenus reports three-year Phase 1b BOT+BAL data at ESMO GI

2026-07-06T11:35:16.000Z - 25 days ago

Agenus reports three-year Phase 1b BOT+BAL data at ESMO GI

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Jul 6, 2026, 7:30 AM EDT - 25 days ago

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Agenus announces three-year survival data from Phase 1b BOT+BAL study

2026-06-25T11:06:14.000Z - 5 weeks ago

Agenus announces three-year survival data from Phase 1b BOT+BAL study

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Jun 25, 2026, 7:00 AM EDT - 5 weeks ago

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Transcript: AGM 2026

Jun 16, 2026, 10:00 AM EDT - 6 weeks ago

Agenus Transcript: AGM 2026

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Jun 2, 2026, 4:30 PM EDT - 2 months ago

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

May 21, 2026, 5:00 PM EDT - 2 months ago

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

May 21, 2026, 5:00 PM EDT - 2 months ago

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus announces publication of Phase 1b BOT+BAL data

2026-05-15T20:23:26.000Z - 2 months ago

Agenus announces publication of Phase 1b BOT+BAL data

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

May 15, 2026, 4:11 PM EDT - 2 months ago

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 2 months ago

Agenus Proxy statement: Proxy filing

Agenus reports Q1 revenue $33.7M vs. $24.1M last year

2026-05-11T14:42:15.000Z - 2 months ago

Agenus reports Q1 revenue $33.7M vs. $24.1M last year

Agenus provides 2026 strategic priorities

2026-05-11T14:38:34.000Z - 2 months ago

Agenus provides 2026 strategic priorities

Agenus announces conclusion of SEC investigation with no enforcement action

2026-05-11T14:36:03.000Z - 2 months ago

Agenus announces conclusion of SEC investigation with no enforcement action

Agenus Earnings release: Q1 2026

May 11, 2026, 9:30 AM EDT - 2 months ago

Agenus Earnings release: Q1 2026

Agenus Quarterly report: Q1 2026

May 11, 2026, 9:30 AM EDT - 2 months ago

Agenus Quarterly report: Q1 2026

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 11, 2026, 8:45 AM EDT - 2 months ago

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

May 4, 2026, 4:30 PM EDT - 3 months ago

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Agenus Proxy statement: Proxy filing

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Apr 21, 2026, 10:00 AM EDT - 3 months ago

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Agenus appoints BAP Pharma as global partner for BOT+BAL access programs

2026-04-21T13:51:54.000Z - 3 months ago

Agenus appoints BAP Pharma as global partner for BOT+BAL access programs

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Agenus Proxy statement: Proxy filing

Agenus reports Phase 2 results from BOT and BAL with agenT-797

2026-04-17T20:51:02.000Z - 3 months ago

Agenus reports Phase 2 results from BOT and BAL with agenT-797

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Apr 17, 2026, 4:43 PM EDT - 3 months ago

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Apr 3, 2026, 7:30 AM EDT - 4 months ago

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL

2026-04-01T11:48:30.000Z - 4 months ago

Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Apr 1, 2026, 7:30 AM EDT - 4 months ago

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Agenus Transcript: AGM 2026

Mar 31, 2026, 4:30 PM EDT - 4 months ago

Agenus Transcript: AGM 2026

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Mar 26, 2026, 4:52 PM EDT - 4 months ago

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Mar 17, 2026, 4:40 PM EDT - 4 months ago

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Agenus Annual report: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 4 months ago

Agenus Annual report: Q4 2025

Agenus Earnings release: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 4 months ago

Agenus Earnings release: Q4 2025

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Mar 16, 2026, 7:30 AM EDT - 4 months ago

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Mar 4, 2026, 4:30 PM EST - 5 months ago

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Feb 19, 2026, 3:15 PM EST - 5 months ago

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Feb 9, 2026, 1:00 PM EST - 6 months ago

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Agenus Transcript: Status update

Jan 28, 2026, 4:00 PM EST - 6 months ago

Agenus Transcript: Status update

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Jan 21, 2026, 7:30 AM EST - 6 months ago

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 6 months ago

Agenus to Host First 2026 Stakeholder Webcast

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Jan 15, 2026, 8:30 AM EST - 7 months ago

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Jan 15, 2026, 7:01 AM EST - 7 months ago

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Jan 12, 2026, 7:30 AM EST - 7 months ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Dec 23, 2025, 8:05 AM EST - 7 months ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Nov 19, 2025, 4:01 PM EST - 9 months ago

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Nov 18, 2025, 8:41 AM EST - 9 months ago

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Agenus Quarterly report: Q3 2025

Nov 10, 2025, 9:30 AM EST - 9 months ago

Agenus Quarterly report: Q3 2025

Agenus Earnings release: Q3 2025

Nov 10, 2025, 9:30 AM EST - 9 months ago

Agenus Earnings release: Q3 2025

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 10, 2025, 7:30 AM EST - 9 months ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Nov 5, 2025, 1:47 PM EST - 9 months ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Agenus Transcript: Status Update

Oct 21, 2025, 4:00 PM EDT - 10 months ago

Agenus Transcript: Status Update

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 17, 2025, 8:00 AM EDT - 10 months ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Oct 16, 2025, 7:48 AM EDT - 10 months ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Agenus Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:00 AM EDT - 11 months ago

Agenus Transcript: H.C. Wainwright 27th Annual Global Investment Conference

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 9, 2025, 7:43 AM EDT - 11 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus Slides: Corporate Presentation

Sep 8, 2025, 7:00 AM EDT - 11 months ago

Agenus Slides: Corporate Presentation

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:52 AM EDT - 11 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Agenus Transcript: Stakeholder Briefing

Aug 27, 2025, 4:00 PM EDT - 1 year ago

Agenus Transcript: Stakeholder Briefing

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 26, 2025, 9:37 AM EDT - 1 year ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 19, 2025, 7:30 AM EDT - 1 year ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Agenus Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Agenus Earnings Call Transcript: Q2 2025

Agenus Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Agenus Quarterly report: Q2 2025

Agenus Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Agenus Earnings release: Q2 2025

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Aug 11, 2025, 7:30 AM EDT - 1 year ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Jul 25, 2025, 12:46 PM EDT - 1 year ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jul 7, 2025, 8:55 AM EDT - 1 year ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 17, 2025, 7:30 AM EDT - 1 year ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 1 year ago

Agenus Announces Virtual Annual Shareholders Meeting

Agenus Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing

Agenus Transcript: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Transcript: Collaboration

Agenus Press release: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Press release: Collaboration

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 30, 2025, 7:30 AM EDT - 1 year ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025, 10:40 AM EDT - 1 year ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Earnings Call Transcript: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings Call Transcript: Q1 2025

Agenus Quarterly report: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Quarterly report: Q1 2025

Agenus Earnings release: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings release: Q1 2025

Agenus Registration statement: Registration Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Agenus Registration statement: Registration Filing

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 1 year ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025, 7:20 AM EDT - 1 year ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

BlackW1d0w
BlackW1d0w Jul. 31 at 9:33 PM
$AGEN The key event will be the initial efficacy data. If those results are far better than current standards of care, the probability of an Accelerated Approval pathway increases meaningfully
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Jul. 31 at 5:13 PM
$AGEN why are we down, that greedy mf using ATM? C’mon commodore tell us the board members!! Wonder how many phone calls commodore has had to make to Agenus since the deal was announced to ask garo “what the fuck are you doing”
2 · Reply
pedmac2000
pedmac2000 Jul. 31 at 4:20 PM
$AGEN profit taking today ?
3 · Reply
Biotechguy21
Biotechguy21 Jul. 31 at 3:49 PM
$AGEN is it classic atm Friday in the ceo/cfo’s world?
0 · Reply
Biotechguy21
Biotechguy21 Jul. 31 at 1:57 PM
$AGEN don’t forget this ceo is responsible for these other pos stocks $INKT $PTIX epic legacy 🤡🤡😂😂💩💩💰💰
0 · Reply
BakerBrother
BakerBrother Jul. 31 at 1:23 PM
$AGEN funding secured and now the sky is the limit
2 · Reply
BakerBrother
BakerBrother Jul. 31 at 1:22 PM
$AGEN Ha ha ha ha ha idiot https://www.cnbc.com/amp/2026/07/30/leopold-aschenbrenners-hedge-fund-is-facing-steep-ai-losses.html
1 · Reply
Stefman9
Stefman9 Jul. 31 at 9:42 AM
$AGEN
1 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 3:16 AM
$AGEN First off my tip to you is NEVER buy biotech shares early. And if you find out that you did buy too early average down, average down, average down. I bought low 2s and even more when under 2. My first purchase was near 5 on the way down. If the science is good and the TAM is respectable stay with it. See TRIB below. .34 to 13.55 figure it out. Garo made me a boat load of cash in the early 2000s with ELAN.
5 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Jul. 31 at 2:51 AM
$AGEN Robbie, why are you such a garo fan boy? After all the reverse splits it would take share price of 100 to break even on original investment, would take share price of 300 dollars to get back to where we’d be if we had only invested in S&P and never stumbled across antigenics until now
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Jul. 31 at 2:47 AM
$AGEN I’d have to double check with ai Robbie’s claims that tigit is back, many tigit molecules failed…AGEN has two tigit molecules, I will check with AI on this when I’ve convinced Robbie that garo is a fucking clown
0 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 2:44 AM
$AGEN Why are all suits and investigations dead? Anyone can sue anyone. Anyone can make claims that will prompt the SEC to act. Nothing Burger
0 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 2:31 AM
$AGEN bot/bal was the prize not TIGIT. Did AGEN nearly go under? Sure did. Shareholder Lawsuits, SEC investigation, Old School FDA shunned them. No cash. No cash. No Cash.
2 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 2:24 AM
$AGEN @A_I_R_IKAZEE I don't know first hand but it's possible. Either way when you anticipate your paycheck on Friday and it isn't there it could disrupt your plans. Eventually it did disrupt Garo's plans. It was a massive hurdle to overcome.
0 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 2:18 AM
$AGEN They work just fine. Wait until Garo puts them on the market again. Worth$BILLIONS.
1 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 2:07 AM
$AGEN Do you think Garo had the funding lined up to move on to P3 without dilution should these milestones stayed in place? Do you think he would have hit the ATM button weekly if these milestones would have stayed in place? By the way TIGIT has returned as viable science. These molecules were developed and the IP is in AGENs pocket today.
3 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 2:01 AM
$AGEN Following these returns, Agenus regained 100% of the global rights to these molecules, allowing them to either re-license them or integrate them into internal combination regimens. This is what Garo had to deal with. Billions in potential revenue up in smoke. All three were returned within weeks if I recall correctly. Was it a concerted effort to sink AGEN? You tell me.
2 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 1:59 AM
$AGEN | **Gilead Sciences** | **AGEN2373** | CD137 Agonist | Mid-2024 | **$570 Million** *($50M option exercise fee + $520M in potential milestones)* | | **Merck (MRK)** | **MK-4830** | Anti-ILT4 Monoclonal Antibody | 2024 | **~$85 Million** *(Remaining milestone eligibility)* | | **Total Potential Value** | | | | **~$1.97 Billion – $2.015 Billion** | ### Key Context Behind the Returns * **BMS (AGEN1777):** BMS acquired rights to AGEN1777 in 2021 for $200M upfront. In August 2024, BMS terminated the agreement as part of a broader corporate cost-cutting measure and industry-wide pullback from TIGIT-targeted immunotherapies. * **Gilead (AGEN2373):** Gilead originally entered into a broad $1.7 billion multi-program partnership with Agenus in 2018. In 2024, Gilead permitted its exclusive option window for AGEN2373 to expire without exercising it. * **Merck (MK-4830):** Merck scaled back and ended active collaboration on MK-4830 in 2024 as part of clinical portfolio prioritization.
1 · Reply
robbiekuss1
robbiekuss1 Jul. 31 at 1:58 AM
$AGEN @A_I_R_IKAZEE Here's what I'm talking about Thin Air Head. Did you forget? In 2024, Agenus (NASDAQ: AGEN) had three major pharmaceutical partners—**Bristol Myers Squibb (BMY)**, **Gilead Sciences**, and **Merck (MRK)**—return rights or allow option agreements to expire for partnered immuno-oncology programs. Collectively, these terminations forfeited approximately **$1.955 billion to $2.015 billion** in potential future option fees, development, regulatory, and commercial milestone payments: ### Breakdown by Partner & Molecule | Partner | Asset / Molecule | Target | Returned / Expired | Total Potential Milestones Returned | | :--- | :--- | :--- | :--- | :--- | | **Bristol Myers Squibb (BMY)** | **AGEN1777** | Anti-TIGIT / CD96 Bispecific | August 2024 | **~$1.315 Billion – $1.36 Billion** *(Up to $1.36B total milestones, with ~$45M realized prior to termination)* |
0 · Reply
BlackW1d0w
BlackW1d0w Jul. 31 at 1:33 AM
$SPY I won’t let you down . I won’t sell you out . I love you Here’s to the bois back home . I wish I was with yall $AGEN
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE Jul. 31 at 1:25 AM
$AGEN garo armens personality is eerily similar to that of Anthony fauci
0 · Reply
weichsel1
weichsel1 Jul. 31 at 1:18 AM
$AGEN Still down only 90 percent over since 2016..
1 · Reply